No validated direct molecular target

The designation 'No validated direct molecular target' is a classification used in pharmacology and drug discovery databases to describe therapeutic agents whose specific molecular binding site—such as a receptor, enzyme, or ion channel—has not been definitively identified or validated (ChEMBL Database, 2024). This classification is frequently applied to drugs discovered via phenotypic screening, where the therapeutic effect is established based on observable cellular or physiological changes rather than a target-centric approach (Moffat et al., 2017, Nature Reviews Drug Discovery). Such agents may operate through complex polypharmacology, non-specific interactions, or by altering the physical properties of biological membranes or fluids. While these drugs can be clinically effective, the absence of a defined target complicates the optimization of potency and the assessment of safety profiles. Over time, advancements in proteomics and chemical biology often allow for the 'deconvolution' of these targets, leading to the eventual identification of the specific proteins involved (Haura et al., 2013, Clinical Cancer Research).

Other names

Unknown molecular targetUnidentified targetPhenotypic targetNon-specific mechanism of action

The mechanism of action is typically characterized by phenotypic changes or physiological responses rather than binding to a specific, identified protein or nucleic acid.